Becton Dickinson and Company ($BDX) Stock Forecast: Up 5.7% Today

What is Becton Dickinson and Company?

Becton Dickinson and Company (BDX) is a leading global medical technology company that manufactures and sells medical devices, instrument systems, and reagents. The company operates through two segments: BD Medical and BD Life Sciences.

Why is Becton Dickinson and Company going up?

BDX stock is up 5.7% on May 7, 2026 17:06

• Today's positive movement of BDX is linked to the company's strong performance in Q2 2026 and the subsequent increase in its revenue outlook for fiscal year 2026.
• The rise in revenue outlook follows a 5.2% year-over-year increase in Q2 revenues to $4.7 billion, highlighting the strength and growth opportunities in BD's varied business segments.
• Despite falling short of analyst projections in adjusted EBITDA and encountering a decrease in operating margin, the market reacted favorably to the revenue and EPS surpassing expectations in Q1 CY2026.
• BD's strategic efforts, including introducing new products and forming partnerships within its Medical Essentials, Connected Care, and Interventional segments, have enhanced investor confidence in the company's future growth prospects.

BDX Price Chart

BDX Technical Analysis

BDX News

BD uplifts FY26 revenue outlook based on steady portfolio performance

Becton Dickinson and Company (BD) has increased its fiscal year 2026 (FY26) profit outlook after reporting strong Q2 2026 financials, with revenues up 5.2% year-over-year to $4.7 billion. This revised outlook, which raises the anticipated FY26 earnings per share to $12.52-$12.72, reverses an earlier trim made in Q1 FY26 due to the divestment of its diagnostics unit. All of BD's business segments saw year-over-year growth, with medical essentials being the largest revenue generator.

https://www.medicaldevice-network.com/news/bd-uplifts-fy26-revenue-outlook-based-on-steady-portfolio-performance/

BD’s (NYSE:BDX) Q1 CY2026 Sales Beat Estimates

Becton, Dickinson and Company (NYSE:BDX) reported better-than-expected revenue and earnings per share for Q1 CY2026, with sales up 5.2% year-on-year to $4.71 billion and adjusted EPS beating estimates. Despite revenue and EPS beats, the adjusted EBITDA missed analyst estimates and the operating margin significantly decreased. The company slightly raised its full-year adjusted EPS guidance, and the stock traded up immediately following the results.

https://stockstory.org/us/stocks/nyse/bdx/news/earnings/bds-nysebdx-q1-cy2026-sales-beat-estimates

BD Reports Second Quarter Fiscal 2026 Financial Results

BD (Becton, Dickinson and Company) announced solid fiscal 2026 second quarter results with revenue of $4.7 billion, up 5.2% as reported, and adjusted diluted EPS of $2.90, exceeding expectations. The company reaffirmed its full-year revenue growth guidance and raised its adjusted diluted EPS guidance based on strong first-half performance and improved visibility. Key business highlights included new product launches and strategic partnerships across its Medical Essentials, Connected Care, and Interventional segments.

https://investors.bd.com/news-events/press-releases/detail/958/bd-reports-second-quarter-fiscal-2026-financial-results

Paracentesis Kit Market Is Going to Boom Rapidly | BD, Merit Medical Systems, Cardinal Health, Teleflex Incorporated

The global paracentesis kit market is projected to grow from USD 1.28 billion in 2026 to USD 2.25 billion by 2033, exhibiting an 8.39% compound annual growth rate. This growth is driven by evolving market dynamics, key investment pockets, and regional performance, as analyzed in a comprehensive report by Coherent Market Insights. The report provides detailed insights into market segmentation, competitive landscape, and future opportunities for business leaders and investors.

https://www.openpr.com/news/4505155/paracentesis-kit-market-is-going-to-boom-rapidly-bd-merit

Earnings Flash (BDX) Becton, Dickinson and Company Reports Q2 Revenue $4.71B, vs. FactSet Est of $4.67B

Becton, Dickinson and Company (BDX) has reported its Q2 revenue, reaching $4.71 billion, which surpassed FactSet's estimated $4.67 billion. The company specializes in medical and diagnostic equipment, with net sales broken down across medical management systems, interventional medical equipment, and diagnostic tools. BDX also announced adjusted EPS of $2.90 per share for the same quarter.

https://www.marketscreener.com/news/earnings-flash-bdx-becton-dickinson-and-company-reports-q2-revenue-4-71b-vs-factset-est-of-4-ce7f58d3dd80ff2c

Trending Today

Silver ($XAG) Commodity Forecast: Down 5.1% Today

SL Green Realty Corp ($SLG) Stock Forecast: Down 5.3% Today

Torchmark Corporation ($GL) Stock Forecast: Down 4.0% Today

Xerox Corporation ($XRX) Stock Forecast: Down 5.2% Today

Akamai Technologies Inc. ($AKAM) Stock Forecast: Down 5.6% Today

Enphase Energy Inc. ($ENPH) Stock Forecast: Down 5.5% Today

Moderna Inc. ($MRNA) Stock Forecast: Down 5.1% Today

Edison International ($EIX) Stock Forecast: Up 7.1% Today

Pacific Gas & Electric Co. ($PCG) Stock Forecast: Up 5.5% Today

Zebra Technologies Corporation ($ZBRA) Stock Forecast: Down 5.5% Today

Becton Dickinson and Company Price History

11.01.2026 - BDX Stock was up 6.2%

• BDX stock exhibited a strong bullish trend despite its underperformance compared to the broader market and healthcare sector ETFs in the previous year.
• Initially facing a decline due to a notable miss in life sciences revenue, the stock later recovered following the surpassing of Q4 2025 revenue and EPS estimates.
• Analysts' consensus rating of "Moderate Buy" and a mean price target indicating an expected 18.8% increase likely influenced the bullish movement.
• The optimistic outlook may also stem from investors' confidence in BDX's growth opportunities and strategic efforts to tackle industry challenges.

11.01.2026 - BDX Stock was up 5.2%

• BDX stock had a strong bullish movement.
• Market reacted positively to BDX's strategic focus on high-growth areas as a "Pure-Play MedTech" company.
• Investors are optimistic about BDX's long-term value creation potential despite short-term concerns over revised earnings guidance for 2026.
• Market may be favorably viewing BDX's restructuring efforts and strategic positioning, driving the bullish movement in the stock price.

05.00.2026 - BDX Stock was up 1.9%

• BDX experienced a strong bullish movement today, likely driven by positive developments.
• A major financial institution raised the price target for BDX shares, indicating confidence in the company's performance and potential upside.
• Recent innovations and advancements such as the first Phasix™ Mesh laparotomy reinforcement case in Greece and progress in the PREVENT clinical trial showcase BD's dedication to improving patient outcomes, potentially contributing to positive investor sentiment.
• An additional $10 million share repurchase program was announced, signaling the company's confidence in its financial position and commitment to returning capital to shareholders, which may have bolstered investor confidence in BDX.

04.01.2026 - BDX Stock was up 2.8%

• BDX saw a notable increase in its stock price today, following the reception of three 2026 Best in KLAS Awards for its medication management technologies. These awards underscore the company's industry leadership and positive feedback from healthcare professionals.
• The strategic decision by Becton, Dickinson and Company to restructure its business by spinning off its Biosciences & Diagnostic Solutions division and merging it with Waters Corporation likely contributed to investor confidence and propelled the stock price upwards.
• Despite Mediolanum International Funds Ltd reducing its holdings in BDX, other institutional investors making adjustments to their positions did not detract from the overall positive outlook on the company.
• Analysts raised the price target for BDX, emphasizing upcoming segment transitions and the company's investments in expanding production capabilities, which further bolstered investor confidence in the stock's future growth prospects.

06.10.2025 - BDX Stock was down 0.8%

• Despite surpassing expectations for earnings and revenue in the quarter, BDX witnessed a decline in its stock value.
• The market's reaction might be linked to uncertainties regarding the company's future growth trajectory or provided guidance.
• Investors could be considering broader factors like global economic conditions or developments within the industry, impacting the stock's downward trend.
• The bearish movement could also be influenced by profit-taking activities or prevailing market sentiment, potentially overshadowing the positive earnings outcome.

10.01.2026 - BDX Stock was down 17.3%

• BDX reported strong Q1 2026 earnings but lowered its full-year guidance, leading to a bearish market sentiment.
• Analysts revised their price targets downwards following the adjusted earnings guidance, contributing to the stock's significant decline.
• Despite a positive outlook on the "new company" and potential upside, the market reacted negatively to the lowered profit guidance due to the sale/spin-off of its Biosciences & Diagnostic Solutions unit.
• The bearish movement of BDX shares was also influenced by the broader market sentiment towards medical technology firms, as seen in the performance of other companies facing challenges with earnings misses and conservative revenue guidance.

23.00.2026 - BDX Stock was down 5.0%

• BDX faced a bearish market movement despite positive third-quarter results, increased dividend, and strong FY2026 EPS guidance.
• The sale of SmartDose rights by a pharmaceutical services company to another entity could have impacted BDX's market sentiment negatively, leading to the bearish movement.
• The launch of BD Research Cloud 7.0 with AI-powered tools for immunology and cancer research, while positive for BD's long-term growth, might not have been enough to offset the overall market sentiment impacting the stock price.
• Investors may have reacted cautiously to the news, potentially waiting for more clarity on how these developments will translate into revenue growth and market competitiveness for BDX in the future.

10.01.2026 - BDX Stock was down 19.0%

• BDX shares fell by 3% after the company lowered its profit outlook for fiscal year 2026, following the completion of the spin-off of its biosciences & diagnostic solutions business which merged with Waters in a $17.5bn agreement.
• An analyst adjusted BDX's price target downwards to $170 from $205, maintaining a Neutral rating, reflecting a shift in the outlook.
• Waters (WAT) received a favorable rating and a $400 price target from an analyst after acquiring BDX's Life Sciences Bioprocessing segment, positioning itself well in the medical diagnostics and research market.
• Despite BDX reporting stronger-than-expected Q1 FY2026 results with profits of $5.25bn, the revised profit outlook and analyst rating adjustments contributed to the bearish movement in the stock today.

10.01.2026 - BDX Stock was down 14.9%

• A financial institution lowered its price target for BDX and maintained a "buy" rating, citing a reduction in profit guidance for FY26 due to the sale/spin-off of a unit, leading to a drop in share price.
• Another financial institution adjusted BDX's price target downwards and maintained a Neutral rating, reflecting a shift in outlook by analyst firms.
• Despite positive sentiment from an industry expert towards the company's recent developments, the market reacted negatively to the lowered profit guidance and revised price targets by multiple analyst firms.
• The bearish movement in BDX's stock could be attributed to the mixed Q4 2025 results reported by another company, which also impacted the broader sentiment in the healthcare sector.

10.11.2025 - BDX Stock was up 2.8%

• An investment firm increased Becton Dickinson's price target to $220 from $215 and maintained a Buy rating, citing positive implications from a transaction with Waters Corporation. This adjustment reflects optimism about the company's future performance.
• The global Pharmacy Automation Systems Market is projected to grow significantly, with key players like BD poised to benefit from the increasing adoption of automation in healthcare.
• Solventum Corporation, a healthcare company spun off from 3M, is garnering attention for its potential turnaround story, which could indirectly impact positively on companies like Becton, Dickinson and Co.
• Despite a reduction in stake by Natixis, institutional investors still hold a significant portion of Becton, Dickinson and Co.'s stock, indicating continued confidence in the company's prospects.

07.04.2026 - BDX Stock was up 5.1%

• BDX's Q2 revenue amounted to $4.71 billion, exceeding projections and reflecting robust demand for its medical and diagnostic equipment.
• With an adjusted EPS of $2.90 per share, BDX outperformed Wall Street predictions, demonstrating strong financial performance.
• The company's upward revision of its full-year earnings forecast and the appointment of a new CFO bolstered investor confidence, driving a bullish trend in the stock.
• Despite a slight decrease in operating margin, the favorable results and optimistic outlook for BDX propelled the stock's rise, eliciting a positive response from investors.

07.04.2026 - BDX Stock was up 5.7%

• Today's positive movement of BDX is linked to the company's strong performance in Q2 2026 and the subsequent increase in its revenue outlook for fiscal year 2026.
• The rise in revenue outlook follows a 5.2% year-over-year increase in Q2 revenues to $4.7 billion, highlighting the strength and growth opportunities in BD's varied business segments.
• Despite falling short of analyst projections in adjusted EBITDA and encountering a decrease in operating margin, the market reacted favorably to the revenue and EPS surpassing expectations in Q1 CY2026.
• BD's strategic efforts, including introducing new products and forming partnerships within its Medical Essentials, Connected Care, and Interventional segments, have enhanced investor confidence in the company's future growth prospects.